FOLR1 and ovarian carcinoma: The primary goal of the current multi-institutional, randomized phase 3 trial is to confirm the efficacy of OTL38 in combination with fluorescent light to detect additional folate receptor-positive ovarian cancer lesions not detected by palpation and visualization under normal light in patients with FRa-positive ovarian cancers scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery.